drugset / Trial / NCT01357447
Pulmozyme for Sjogren's Associated Cough
RandomizedCrossoverDouble-blindSupportive care
Summary
Patients with Sjogren's disease have destruction of the mucus secreting cells in the airway. This manifestation of the disease leads to the common complaint of persistent dry cough that is seen in many of these patients. This study is aimed at determining whether the regular use of Pulmozyme will result in decreased cough and improved quality of life.
Timeline
- Start
- 2011-05
- Primary completion
- 2012-03
- Completion
- 2012-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | dornase alfa | Protein / enzyme biologic | 2.5 mg | Inhaled |